Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 189,708

Document Document Title
WO/2021/089554A1
The present disclosure relates to the use of a novel dosage form of merotocin in improving lactation in a female in need thereof. The disclosure particularly provides the use of a composition suitable for intranasal administration that p...  
WO/2021/092471A1
Provided herein are compositions comprising a vaccine composition and an agent that triggers metabolic reprogramming of B cells and methods of using the agent that triggers metabolic reprogramming of B cells to increase effectiveness of ...  
WO/2021/092090A1
Disclosed herein are methods for palmar or plantar administration of anticholinergic compounds to a subject in need thereof. Also disclosed herein are methods of treating palmar or plantar hyperhidrosis in a subject in need thereof by ad...  
WO/2021/092589A1
The disclosed subject matter provides for genetically modified cells, e.g, fungal cells, that autonomously generates and/or secretes one or more therapeutic molecules, e.g, therapeutic peptides, therapeutic proteins or small therapeutic ...  
WO/2021/090855A1
The following were discovered: a cyclic peptide compound that interacts with Ras; and an unnatural amino acid that is useful in the production of said cyclic peptide compound. The cyclic peptide compound was also discovered to inhibit bo...  
WO/2021/090552A1
One embodiment of the present invention pertains to an enteric preparation containing milk-derived lactoferrin that has a lactoferrin monomer (A) peak area ratio of 62% or more and a low-molecular weight aggregate (B) peak area ratio of ...  
WO/2021/089721A1
The invention is in the field of medical interventions, more in particular the treatment, amelioration or prevention of viral infections, such as flavivirus infections, more in particular of infections with ZIKA virus. More in particular...  
WO/2021/067404A3
CH1 domain variants engineered for preferential binding to either a kappa CL domain or a lambda CL domain, as well as polypeptides, e.g., antibody heavy chains or antibodies, comprising such engineered CH1 domain variants, and pharmaceut...  
WO/2021/090959A1
The present invention provides a substituted polypeptide having the effect of inhibiting MMP2 and represented by formula [I'], or a pharmaceutically acceptable salt thereof.  
WO/2021/091356A1
The present invention relates to a pharmaceutical composition, a functional food composition, and a cosmetic composition which include methyl benzoate or a derivative thereof as an active ingredient, and are for preventing or treating st...  
WO/2021/090911A1
Provided are: a method for selectively killing protein aggregate-containing cells; a kit therefor; a therapeutic drug for protein misfolding diseases; and a drug product for removing protein aggregates from a blood product. The method fo...  
WO/2021/088739A1
A method and a device for determining an intestinal probiotic supplement formula, a storage medium, and a processor. The method comprises dividing intestinal probiotics into a plurality of probiotic groups, and dividing each probiotic gr...  
WO/2021/085232A1
[Problem] Provided is a composition useful for treating and/or preventing neurodegenerative disorders such as Alzheimer's disease and Parkinson's disease. [Solution] This composition is for treating and/or preventing neurodegenerative di...  
WO/2021/084791A1
The purpose of the invention is to identify a new receptor participating in the differentiation of helper T cells and to develop a drug targeted thereto. It has been discovered that an adenosine A2A receptor participates in control of th...  
WO/2021/085291A1
The purpose of the present invention is to provide: a composition for TGR5 activation, said composition comprising, as an active ingredient, a substance that has an effect of activating TGR5 and shows a high selectivity for TGR5; and a m...  
WO/2021/085496A1
Disclosed are an antioxidant agent, an antisaccharification agent, a neurite outgrowth promoter, and a cognitive function improver which contain propolis and gingko leaf extract as active ingredients.  
WO/2021/085504A1
Provided are a B-cell antibody receptor (BAR), a BAR-T cell and others which are effective for the treatment of diseases associated with antibodies produced in the bodies of patients. The B-cell antibody receptor (BAR) according to the p...  
WO/2021/049496A9
The present invention addresses the problem of providing technology for inhibiting cancer stem cells. Provided is a composition including at least one substance selected from the group consisting of pterostilbene and glycosides thereof.  
WO/2021/085582A1
A problem addressed by the present invention is to provide a compound useful as an antitumor agent, etc., and a pharmaceutical composition, antitumor agent, and dihydroorotate dehydrogenase inhibitor that include the compound. The presen...  
WO/2021/084665A1
An agent effective in promoting production of PDGF-BB, and an agent which, using that agent, is effective for activation and anti-aging of the skin through stabilization of mesenchymal stem cells in the skin are provided. The PDGF-BB pro...  
WO/2021/085639A1
The purpose of the present invention is to provide a novel medical application using pluripotent stem cells in regenerative medicine. The present invention provides a cell formulation and pharmaceutical composition that are for ameliorat...  
WO/2021/062389A3
A peptide is disclosed that has an amino acid sequence selected from X1-X2-X3-Gln-Leu-Met- Leu-Cys-Val-Leu-X4-X5-X6 (SEQ ID NO: 3), X1-X2-X3-Gln-X7-Met-X10-Cys-Val-X11-X4-X5- X6 (SEQ ID NO: 4), Ile-Ser-Phe-Gln-Leu-Met-Leu (SEQ ID NO: 5),...  
WO/2021/087291A1
Various aspects of this patent document relate to the newly-discovered organic oxide class of pharmaceuticals.  
WO/2021/085528A1
Provided is a CD4 mimic compound which has more improved in vivo kinetics and improved efficacy in anti-HIV treatment. Provided are: a compound represented by formula (I) [in the formula, R1 represents -C2H4(OC2H4)n-OCH3 or CmH2m+1, R2...  
WO/2021/084869A1
Provided are: a manufacturing method for an electrolyte that can contain microbubbles at a high concentration by suppressing a reduction in microbubbles during filtering; and a manufacturing method for a microbubble-containing solvent th...  
WO/2021/085252A1
The present invention provides a medicine for an inflammatory pulmonary disease that is capable of effectively preventing and/or treating an inflammatory pulmonary disease. More specifically, the present invention pertains to a prophylac...  
WO/2021/079983A1
The inventors of the present application have found that a compound represented by formula (I) has the effect of protecting cartilage. Therefore, provided is a pharmaceutical composition that is for protecting cartilage and that contains...  
WO/2021/078889A1
The invention relates to compounds of the formula (I) and pharmaceutically acceptable salts thereof for the use in the treatment of sickle cell disease and for the use in preventing and treating vascular inflammation and vaso-occlusion.  
WO/2021/080331A1
The present invention relates to a composition for enhancing a survival rate of stem cells, comprising an immunosuppressant, and to a use thereof. The present invention confirmed that an immune response occurs in mice administered with h...  
WO/2021/079988A1
This agent for promoting odontoblast propagation and differentiation contains a calcium salt of 4-(meth)acryloyloxyethyltrimellitic acid.  
WO/2021/081403A1
Provided are methods for preparing samples for sequencing. Also provided are methods for sequence analysis. Also provided are methods for classifying multiple aspects of a nucleotide repeat expansion disorder in a single sequencing assay...  
WO/2021/079987A1
The present invention relates to a muscle quality improvement agent that contains a γ-glutamyl peptide. This invention makes it possible to provide a muscle quality improvement agent that can prevent a decrease in muscle quality or impr...  
WO/2021/079921A1
Provided are: a growth inhibitor against pathogenic bacteria in the oral cavity and to be added to a composition for the oral cavity; an oral microflora improver; and a composition for the oral cavity using the growth inhibitor and the o...  
WO/2021/079536A1
This composition for lysis of Staphylococcus aureus or this composition for prevention or therapy of diseases caused by Staphylococcus aureus contains as active ingredients: at least one bacteriophage selected from the group consisting o...  
WO/2021/078959A1
The present invention relates to a competitive antagonist antibody that specifically binds to AMHR-II, said antibody comprising (a) a heavy chain wherein the variable domain comprises a H-CDR1 having a sequence set forth as SEQ ID NO: 3;...  
WO/2021/079958A1
Provided are a pharmaceutical composition and the like for use in treatment or prevention of cancer. The pharmaceutical composition and treatment method for treatment of cancer are characterized in that an anti-GARP antibody and an immun...  
WO/2021/081296A1
Provided herein are methods, compositions, kits, and systems for detecting Epstein Barr virus infection (EBV) in gastric cancer (GC) patients. In particular, provided herein are methods, composition, kits, and systems for diagnosing and ...  
WO/2021/079986A1
A composition for lysing Staphylococcus aureus or a composition for preventing or treating a disease caused by Staphylococcus aureus, said composition comprising, as active ingredients, at least one bacteriophage selected from the group ...  
WO/2021/079984A1
The present invention provides a novel compound having an excellent β-lactamase inhibitory effect. The present invention provides: a compound which has an excellent β-lactamase inhibitory effect, and is represented by formula (1a), (1b...  
WO/2021/078986A1
The present invention relates to a composition comprising fibrinogen for increasing the sensitivity of microorganisms for an antimicrobial compound. The invention may be used to alleviate the problem of antimicrobial resistance of microb...  
WO/2021/075535A1
The present disclosure provides a diabetes therapy targeting abnormal stem cells. In one embodiment, the present disclosure provides a therapy for diabetes and/or a disease, a disorder and/or a symptom relating to diabetes, said therapy ...  
WO/2021/075147A1
Provided is a novel BRAP2 action enhancer that is useful for inhibiting both the Ras/Raf/MEK/ERK pathway and the PI3K/Akt/mTOR pathway, the BRAP2 action enhancer comprising, as an active ingredient, a compound represented by formula (1) ...  
WO/2021/074281A1
Disclosed are TRPM8 modulators as defined by formula (I) for achieving a cooling effect on skin and mucousa.  
WO/2021/076675A1
Embodiments of the disclosure include methods and compositions related to prevention of spontaneous miscarriage in an individual. In certain cases, fibroblasts are provided in an effective amount to an individual in need thereof. Alterna...  
WO/2021/076654A1
The present application relates to a method of screening a subject (and/or treating a subject) for a disease. The application further relates to cells and kits for determination of a disease. Also contemplated are treatments, including t...  
WO/2021/075219A1
The purpose of the present invention is to provide a hair growth stimulant that is an external preparation facilitating hair shaft growth in head hair, eyebrows and/or eyelashes and promoting the expression of a gene contributing to hair...  
WO/2021/076966A1
Kynureninase enzymes covalently bound to polyethylene glycol are described. Aspects of the disclosure provide compositions and methods for improving the effective treatment of cancer by way of kynurenine depletion using such molecules.  
WO/2021/075559A1
The present invention elucidates the interaction of FOXO1 in CAFs, and provides a novel therapeutic drug. This cell growth inhibitor for CAFs or this cell death inducer for CAFs contains an FOXO1 inhibitor as an active ingredient.  
WO/2021/075494A1
The present invention addresses the problem of finding a method for reliably producing (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride, wherein crystalline polymorphs can be controlled with industrially easy operation...  
WO/2021/074431A1
A probiotic composition is provided comprising at least two isolated bacterial species or comprising a purified bacterial preparation comprising at least two bacterial species, wherein the at least two bacterial species are selected from...  

Matches 1 - 50 out of 189,708